

Highlight: New TB diagnostic proves effective, expedient, study finds

September 1 2010

A molecular test designed to easily diagnose tuberculosis (TB) and detect a drug-resistant form of the bacterium that causes TB can provide much more specific, sensitive and rapid results than currently available TB diagnostics, according to a new study in the *New England Journal of Medicine*.

In a test involving 1,730 patients with suspected drug-sensitive or multidrug-resistant <u>pulmonary TB</u>, the Xpert MTB/RIF TB test successfully identified 98 percent of all confirmed TB cases and 98 percent of patients with rifampin-resistant bacteria in less than two hours.

TB remains one of the major causes of disability and death worldwide, with an estimated 1.8 million deaths in 2008 and an increasing incidence of drug-resistant disease. New, less costly tools to rapidly diagnose TB and its drug-resistant forms are urgently needed to help stem the tide of new infections.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has supported the development of this diagnostics technology since 2002. This support was critical to the public-private partnership that led to the Xpert MTB/RIF TB test. The current clinical trial findings are from a study conducted by the Foundation for Innovative New Diagnostics (FIND), a Swiss-based nonprofit organization. NIAID currently supports a partnership project to expand the diagnostic system to detect other resistance markers for



extensively drug-resistant TB.

More information: CC Boehme et al. Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine. DOI:10.1056/NEJMoa0907847 (2010).

Provided by National Institutes of Health

Citation: Highlight: New TB diagnostic proves effective, expedient, study finds (2010, September 1) retrieved 19 April 2024 from https://medicalxpress.com/news/2010-09-highlight-tb-diagnostic-effective-expedient.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.